and 9 were followed-up for less than 3 years. Changes in hormone levels and BMD, according to HT regimen, were evaluated in 234 patients. Results: The mean age at transplantation was 30.47 ± 6.55 years. Out of 234 patients, 170 (72.6%) patients received HT, starting treatment at a mean of 15.1 ± 8.2 months after transplantation. A significant increase in estradiol level was observed in patients receiving HT (p < 0.001); no difference was observed between the 3 different types of HT regimen (p = 0.534). After 2 years of HT, BMD was significantly increased at all measurement sites: lumbar spine 5.8 ± 6.26% (p < 0.001), femoral neck 3.4 ± 17.78% (p = 0.037), total hip 2.1 ± 7.15% (p = 0.001). Again, there was no difference in changes between the HT regimens (p = 0.646 for lumbar spine, p = 0.840 for femoral neck, and p = 0.855 for total hip). These changes were significant even in patients with graft versus host disease (GVHD) or steroid exposure. Conclusion: In patients with premature ovarian failure following allogenic HSCT, HT effectively lowered serum FSH and increased serum estradiol levels. HT significantly increased BMD regardless of the history of GVHD or steroid exposure. These changes in hormones and BMD were independent of the HT regimen.

**Pediatric Endocrinology**

**PEDIATRIC ENDOCRINE CASE REPORTS II**

**Prepubertal Gynecomastia Secondary to Excessive Soy Consumption**

Jessica Sea, PhD¹, Mikayel Abramyan, MD², Harvey Kenn Chiu, MD².

¹Univ. of CA, Irvine, Irvine, CA, USA, ²Pediatrics Associates Medical Group, Sherman Oaks, CA, USA, ³UCLA School of Medicine, Los Angeles, CA, USA.

**MON-079**

Enlargement of breast tissue in males, or gynecomastia, is a rare condition in prepubescent boys. While the majority of cases are idiopathic, we describe an 8-year-old patient who developed unilateral gynecomastia secondary to marked dietary soy consumption. Soy products, particularly those consumed by our patient, contain high levels of phytoestrogens which have been documented in limited case studies to contribute to abnormal development of breast tissue in adolescent and adult males. To our knowledge, this is the first documented case of gynecomastia occurring in a prepubescent patient resulting from excessive intake of dietary soy. Importantly, we also report a complete resolution of gynecomastia upon exclusion of dietary products containing significant amounts of soy. While soybeans and soy-derived products can be an important source of nutrition for some, those with abnormal sensitivity to phytoestrogens may benefit from limiting dietary soy consumption to avoid potential adverse effects, including gynecomastia.

**Thyroid**

**THYROID NEOPLASIA AND CANCER**

**Characterization of the Angiogenic Factor SFRP2 in Papillary Thyroid Carcinoma**

Wynn O. Wofford, BS, Rupak Mukherjee, PhD, Julie Siegel, MD, Denise Garcia, MD, MED, Eleanor Hilliard, BS, Patrick Naserre, PhD, Nancy Klauber-DeMore, MD, Mahsa Javid, MD, PhD.

Medical University of South Carolina, Charleston, SC, USA.

**MON-532**

Over the last decade, there has been an average annual increase of 3.1% in thyroid cancer diagnosis in the U.S. Papillary thyroid carcinoma (PTC) accounts for 80% of all thyroid cancer diagnoses. However, few molecular markers exist to identify clinically aggressive phenotypes. The angiogenic factor, secreted frizzled-related protein 2 (SFRP2), is associated with a poor prognosis in several malignancies including breast cancer and melanoma. The role of SFRP2 in PTC has yet to be investigated. The aims of this study were to determine the differential expression of SFRP2 in PTC, benign thyroid adenomas, normal thyroid tissue (from patients without cancer), and normal adjacent tissue (NAT) (non-cancerous tissue from patients with PTC) and investigate the role of SFRP2 in tumor development in two PTC cell lines, PTC classical variant (PTC-CV) and PTC follicular variant (PTC-FV), upon treatment with a humanized anti-SFRP2 monoclonal antibody (hSFRP2 mAb). Immunohistochemistry (IHC) was performed using human tissue protein microarrays including 226 PTC, 79 benign adenomas, 112 NAT, and 30 normal thyroid tissue samples. In-vitro proliferation and apoptosis experiments were performed on MDA-T41 (PTC-CV) and MDA-T68 (PTC-FV) cell lines by treating with hSFRP2 mAb, Xolair IgG control, and a vehicle control. SFRP2 expression was significantly higher in PTC compared with benign adenomas and normal thyroid (mean expression scores 9, 6, and 1, respectively; p<0.05). SFRP2 expression was significantly higher in NAT than normal thyroid (mean expression score 4 and 0, respectively, p<0.05). Apoptotic rates were increased by 40% and 62% in the PTC-CV hSFRP2 mAb treatment group compared with the Xolair and vehicle treatment groups, respectively (p<0.05). Apoptotic rates were increased by 126% and 59% in the PTC-FV hSFRP2 mAb treatment group compared with the Xolair and vehicle treatment groups, respectively (p<0.05). Treatment with hSFRP2 mAb had no significant effect on proliferation in either cell line. In conclusion, SFRP2 expression is significantly higher in PTC than in benign adenomas and normal thyroid tissue. SFRP2 expression in NAT is significantly higher than in normal thyroid tissue and not significantly different from benign adenomas. SFRP2 expression in nonmalignant tissue adjacent to PTC could be due to expression in the tumor microenvironment. Treatment with a novel hSFRP2 mAb increases apoptotic rates in two different PTC cell lines. These data suggest that SFRP2 is involved in tumorigenesis of PTC.

**Reproductive Endocrinology**

**HYPERANDROGENISM**

**No Difference in Breastfeeding Rates in Women with Polycystic Ovary Syndrome**

Leeann Bui, BA, Laura Cooney, MD, Jen Birstler, MS.

UNIVERSITY OF WISCONSIN MADISON, Madison, WI, USA.

**SUN-018**

No Difference in Breastfeeding Rates in Women with Polycystic Ovary Syndrome

Objective: Women with PCOS have increased rates of obesity and gestational weight gain compared to women...
Neuroendocrinology and Pituitary
PITUITARY AND NEUROENDOCRINE CLINICAL TRIALS AND STUDIES

Dynamic Interactions Between Luteinizing Hormone and Testosterone in Healthy Community-Dwelling Men: Impact by Age and Body Composition.

Ferdinand Roelfsema, PHD, MD\(^1\), Peter Y. Liu, PHD, MBBS\(^2\), Paul Takahashi, MD\(^3\), Rebecca Yang, RN\(^4\), Johannes D. Veldhuis, MD\(^5\).

\(^1\)Leiden University Medical Center, Leiden, Netherlands, \(^2\)Los Angeles Biomedical Research Institute, Torrance, CA, USA, \(^3\)Mayo Clinic, Rochester, MN, USA, \(^4\)Endocrine Research Unit, Mayo School of Graduate Medical Education, Center for Translational Science Activities, Mayo Clinic, Rochester, MN, USA, \(^5\)Mayo Clinic & Grad Sch of Med, Boise, ID, USA.

OR32-04

Context. Aging is associated with diminished testosterone (Te) secretion, which could be attributed to Leydig cell dysfunction, decreased pituitary stimulation and altered Te feedback. Objective. The goal was to quantify all three regulatory nodes of the GnRH-LH-Leydig cell- axis in the same cohort of healthy men, by measuring (1) indirectly the strength of the endogenous GnRH signal on the gonadotrope, (2) the strength of Te feedback on LH by ketoconazole (KTCZ), and (3) the effect of LH infusions on Te secretion, in relation to age and body composition.

Design. This was a placebo-controlled, blinded, prospectively randomized cross-over study in 40 men, age 19–73 yr, BMI 20–34.3 kg/m\(^2\). A submaximal dose of ganirelix (GnRH antagonist) was used to assess outflow of GnRH, by calculating the difference between LH output during the control and ganirelix arm. Ketoconazole (steroidogenic inhibitor) was used to estimate feedback, by the difference in LH output during ketoconazole and control arm. High-dose ganirelix and repeated 6-min LH (18.75 IU) infusions were used to measure testicular responsivity. Blood sampling was at 10-min intervals. The 4 sessions were concluded with, a single submaximally GnRH stimulus to assess the responsiveness of the gonadotrope during ganirelix inhibition.

Setting. The study was performed in a Clinical Translational Research Unit.

Interventions. In 3 of the 4 experiments subjects underwent 5 h of blood sampling at 10-min intervals, starting at 0800 h. At 1100 h GnRH was injected and sampling was continued for another 2 h. Admission was at 1700 h the day before. At 2000 h they received KTCZ, dexamethasone and/or placebo. KTCZ and dexamethasone (or placebo) were administered again at 0700 when the IV catheter was placed. High-dose ganirelix was used to test the testicular responsivity, and 7 LH pulses (90 min intervals) were given., with blood sampling from 1500 till 1300 h next day.

Outcome measures. Mean concentrations of LH and (bio)Te, deconvolution analysis, endogenous dose-response LH-bioTe relation, and approximate entropy. Abdominal visceral fat (AVF) was calculated from single slice CT.

Results. There were age-, but not body composition-related decreases in estimated endogenous GnRH secretion, Te's feedback strength on LH, and Leydig cell responsivity to LH, accompanied by changes in approximate entropy. Bioavailable Te levels were negatively related to both age and AVF, without interaction between these variables. The LH response to a submaximal dose of GnRH was independent of age and AVF.

Conclusion. Advancing age is associated with 1) attenuated bioavailable Te secretion caused by diminished GnRH outflow and not by decreased GnRH responsivity of the gonadotrope, 2) diminished testicular responsivity to infused LH pulses, and 3) partial compensation by diminished Te feedback on central gonadotropic regulation.

Cardiovascular Endocrinology
FROM BEDSIDE TO BENCH AND BACK AGAIN: LIPID METABOLISM & VASCULAR DISEASE

Leptin Decreases De Novo Lipogenesis in Lipodystrophic Patients

Annah Petek Baykal, B.S.\(^1\), Elizabeth J. Parks, PHD\(^2\), Robert Shambarek, MD\(^3\), Stephanie Chung, M.B.B.S.\(^3\),

\(^1\)Mayo Clinic, Rochester, MN, USA, \(^2\)Endocrine Research Unit, Mayo School of Graduate Medical Education, Center for Translational Science Activities, Mayo Clinic, Rochester, MN, USA, \(^3\)Mayo Clinic & Grad Sch of Med, Boise, ID, USA.